Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
771.120.17%
QQQ
716.510.11%
BTC/USD
64532.020.1028%
DIA
543.750.17%
GLD
392.420.71%
TLT
83.050.06%

Neuphoria Therapeutics Inc

NEUPNASDAQ
Trade with Public
Trade with Public
$3.95
0.061.54%
At close: Aug 5, 5:00 PM EST
$3.77
-0.18-4.58%
After Hours: 8:45 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Neuphoria Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neuphoria Therapeutics (NEUP).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

1Buy
1Hold
Consensus RatingBuy# Analysts2Avg. Consensus PT$35Upside to Avg. PT+828.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 15, 2026HC Wainwright & Co.Joseph PantginisDowngradeBuy→Neutral—
Dec 5, 2025HC Wainwright & Co.Joseph PantginisPT CutBuy$21→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ:NEUP) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and lowers the price target from $21 to $7.
Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35

Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $18 to $35.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Neuphoria Therapeutics, Maintains $21 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and maintains $21 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $21

HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $8 to $21.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved